Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07386847 · ClinicalTrials.gov registry record

A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

A clinical trial, sponsored by Pfizer.

Completed
Registry status
1
Enrollment target

NCT07386847 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07386847 has completed, sponsored by Pfizer.

COMPLETED
Registry status
1 participants
Enrollment target

Study Summary

Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer. The purpose of this study is to examine how long it takes for adults with advanced or metastatic bladder cancer to experience worsening of their disease following their first treatment . The researchers will also describe which medicines these patients use as their first treatment for the disease. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database who: * Were identified to have advanced or metastatic bladder cancer. * Started their first treatment after 01 Apr 2023. * Were 18 years of age or older when they were diagnosed with advanced disease.

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2026-02-12
Est. Completion 2026-03-30

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT07386847

The ClinicalTrials.gov registry entry for NCT07386847 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT07386847 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07386847 about?

NCT07386847 is a clinical study titled "A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer". Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bl...

What is the current status of trial NCT07386847?

This trial is currently completed. The enrollment target is 1 participants. The study started on 2026-02-12. Estimated completion is 2026-03-30.

Who is sponsoring clinical trial NCT07386847?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.